Search results

Filters
Close
ADDED DATE
Added date
TOPICS Please select
WATCH / LISTEN / READ TIME
Oral P2Y12 Inhibitors and Drug Interactions
Author(s): Elisabetta Bigagli , Jacopo Angelini , Alessandro Mugelli , et al Added: 5 months ago

Anticoagulation

Prevention & Chronic Conditions
Cardiovascular Drug Interactions with Nirmatrelvir/Ritonavir for COVID-19
Author(s): Andrea Di Lenarda , Nicola Ferri , Massimiliano Lanzafame , et al Added: 1 year ago

COVID-19

CV Disease in Special Populations
ESC 25: SWEDEPAD 1 and 2
Author(s): Marten Falkenberg , Joakim Nordanstig Added: 2 months ago
ESC Congress 2025 - Paclitaxel-coated devices in critical limb threatening ischemia were not effective in preventing amputation, nor improving quality-of-life in intermittent claudication.Dr Mårten Falkenberg (Sahlgrenska University Hospital, Gothenburg, SE) and Prof Joakim Nordanstig (Sahlgrenska University Hospital, Gothenburg, SE) join us to discuss findings from the SWEDEPAD 1 and 2 parallel… View more

Intervention

Vascular Disease and Surgery
Cardiovascular Effects of NSAIDs: A Review With a Focus on RA Patients
Author(s): Eirik Ikdahl , Anne Kerola , Eli Sollerud , et al Added: 10 months ago

Prevention & Chronic Conditions
Author(s): Byoung Geol Choi , Seung-Woon Rha , Se Yeon Choi , et al Added: 1 year ago

Anticoagulation
Michel Burnier
Research Area(s) / Expertise: Job title: Emeritus Professor of Medicine & Former Head of the Division of Nephrology and Hypertension
Prof Michel Burnier, MD, is Emeritus Professor of Medicine and former Head of the Division of Nephrology and Hypertension at the University Hospital of Lausanne, Switzerland and Invited Professor at the Medical University of Gdansk, Poland.He trained in internal medicine and nephrology in Lausanne (CH) and at the University of Colorado Health Science Center, Denver, Colorado (US). He is a member… View more
AHA 25 Late-breaking Discussion: The BETTER-BP Trial
Author(s): John Dodson , Harriette Van Spall Added: 2 days ago
AHA Scientific Sessions 2025 — Late-breaker host Dr Harriette Van Spall (McMaster University, Hamilton, CA) is joined by BETTER-BP Principal Investigator Dr John Dodson (NYU Langone Health, New York, US) to present the findings of this AHA late-breaking trial (NCT04114669).The BETTER-BP (Behavioral Economics Trial to Enhance Regulation of Blood Pressure) is a phase II pragmatic randomized… View more

Prevention & Chronic Conditions
AHA 25: The POLY-HF Trial
Author(s): Ambarish Pandey Added: 1 day ago
AHA Scientific Sessions 2025 – Dr Ambarish Pandey (University of Texas Southwestern Medical Center, US) presents results from the POLY-HF trial (NCT04633005), evaluating a polypill strategy combining multiple evidence-based medications for heart failure with reduced ejection fraction.This single-center randomized trial enrolled 212 patients with HFrEF (ejection fraction ≤40%) who were not… View more

Heart Failure
AHA Scientific Sessions 2025 Late-Breaking and Featured Science Collection
Author(s): Ambarish Pandey Added: 6 days ago
Stay at the forefront of cardiovascular medicine with our comprehensive video collection from the American Heart Association's Scientific Sessions 2025. Access expert analysis of the most impactful late-breaking trials and featured science shaping clinical practice.Late-Breaker Discussions: Watch Dr Harriette Van Spall break down pivotal clinical trial data and explore its implications for… View more

Cardiovascular Renal Metabolic

Heart Failure
Systematic Scoping on DOACS in NVAF Patients
Author(s): Shirley Siang Ning Tan , Wei Hong Lai , Lee Len Tiong , et al Added: 3 months ago

Anticoagulation

Electrophysiology & Arrhythmia